Clinical significance is evidenced by human trials indicating that AP administration reduced anti-inflammatory effects in sepsis and ulcerative colitis.56, 57, 58 GM6001 administration also reversed coagulopathic changes as evidenced by blocking the induction of fibrinogen and FXI activity and preventing consumption of multiple coagulation factors (e.g., FII, FV, FIX, FX). The gene discussed is F11; the disease is ulcerative colitis.